waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).

被引：0
|
作者：
Lavie, David
Ozcan, Muhit
Paszkiewicz-Kozik, Ewa
Barca, Eva Gonzalez
Kim, Tae Min
Puccini, Benedetta
Wang, Siruo
Yusuf, Rushdia
Marinello, Patricia
Kim, Won Seog
机构：
[1] Hadassah Med Ctr, Jerusalem, Israel
[2] Ankara Univ, Sch Med, Ankara, Turkiye
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[4] Univ Barcelona, Inst Catala Oncol Hosp, IDIBELL, Barcelona, Spain
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Unit AOU Careggi, Florence, Italy
[7] Merck & Co Inc, Rahway, NJ USA
[8] Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7589
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
    Forero-Torres, Andres
    Kolibaba, Kathryn S.
    Lamy, Thierry
    Jones, Surai
    Lee, Calvin
    Sharman, Jeff
    BLOOD, 2016, 128 (22)
  • [22] A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
    Micallef, I. N.
    Maurer, M. J.
    Nikcevich, D. A.
    Cannon, M.
    Moore, D. F., Jr.
    Kurtin, P.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
    Friedberg, Jonathan W.
    Thompson, Carrie A.
    Trneny, Marek
    Morschhauser, Franck
    Salles, Gilles
    Reagan, Patrick M.
    Hertzberg, Mark
    Smolewski, Piotr
    Zhang, Huilai
    Thieblemont, Catherine
    Hu, Bei
    Fonseca, Gustavo
    Kim, Won-Seog
    Martelli, Maurizio
    Mehta, Amitkumar
    Campinha-Bacote, Avrita
    Yan, Mark
    Hirata, Jamie
    Sugidono, Matthew
    Lee, Calvin
    Sharman, Jeff P.
    BLOOD, 2022, 140 : 6623 - 6626
  • [24] Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
    Ozcan, Muhit
    Lee, Seung Tae
    Mensah, Felix
    Modi, Dipenkumar
    Fossa, Alexander
    Kim, Won Seog
    Paszkiewicz-Kozik, Ewa
    Sawalha, Yazeed
    Sevindik, Omur Gokmen
    Norasetthada, Lalita
    Santoro, Armando
    Pathiraja, Kumudu
    Chakraborty, Samhita
    Marinello, Patricia
    Lavie, David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study
    Zhao, Peiqi
    Zhao, Shu
    Huang, Chen
    Li, Yajun
    Wang, Jiesong
    Xu, Junqing
    Li, Lanfang
    Qian, Zhengzi
    Li, Wei
    Zhou, Shiyong
    Qiu, Lihua
    Liu, Xianming
    Chen, Ying
    Jiang, Yanan
    Zheng, Yanbin
    Chen, Daoguang
    Zhou, Hui
    Gao, Yuhuan
    Zhang, Qingyuan
    Zhang, Huilai
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
  • [26] Glofitamab plus Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study
    Dickinson, Michael
    Viardot, Andreas
    Marks, Reinhard
    Topp, Max S.
    Morschhauser, Franck
    Jacobs, Benedikt
    Tani, Monica
    Bosch, Francesc
    Esteban, Daniel
    Cordoba, Raul
    Kaufman, Derrick
    Wu, Chun
    Humphrey, Kathryn
    Baumlin, Pauline
    Barrett, Martin
    Qayum, Naseer
    Pinto, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study
    Ozcan, Muhit
    Lv, Fangfang
    Norasetthada, Lalita
    Paszkiewicz-Kozik, Ewa
    Schmidt, Joaquin Diaz
    Modi, Dipenkumar
    Fossa, Alexander
    Goyal, Sagun
    Kim, Won Seog
    Lee, Seung Tae
    Santoro, Armando
    Sonmez, Mehmet
    Pathiraja, Kumudu
    Reddy, Nishitha
    Marinello, Patricia
    Song, Yuqin
    BLOOD, 2023, 142
  • [28] Efficacy and Safety of Reduced-Dose Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone ( Pola-R-CHP) in Patients over 80 with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    Miyao, Kotaro
    Wakayama, Tomoyoshi
    Ozaki, Somi
    Numata, Masaya
    Negishi, Shuto
    Ohara, Fumiya
    Motegi, Kenta
    Wakabayashi, Hiroya
    Sawa, Hitomi
    Sakai, Toshiyasu
    Inagaki, Yuichiro
    Sawa, Masashi
    BLOOD, 2023, 142
  • [29] Promising results of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
    Micallef, I. N.
    Maurer, M.
    Nikcevich, D.
    Cannon, M.
    Moore, D.
    Kurtin, P.
    Schaefer, E.
    Witzig, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 161 - 161
  • [30] Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.
    Kambhampati, Swetha
    Saumoy, Monica
    Pak, Stacy
    Budde, L. Elizabeth
    Mei, Matthew Genyeh
    Popplewell, Leslie
    Wen, Yi-Ping
    Forman, Stephen J.
    Kwak, Larry W.
    Rosen, Steven T.
    Herrera, Alex Francisco
    Thiruvengadam, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345